AP2015008893A0 - Stabilized soluble pre-fusion rsv f polypeptides - Google Patents
Stabilized soluble pre-fusion rsv f polypeptidesInfo
- Publication number
- AP2015008893A0 AP2015008893A0 AP2015008893A AP2015008893A AP2015008893A0 AP 2015008893 A0 AP2015008893 A0 AP 2015008893A0 AP 2015008893 A AP2015008893 A AP 2015008893A AP 2015008893 A AP2015008893 A AP 2015008893A AP 2015008893 A0 AP2015008893 A0 AP 2015008893A0
- Authority
- AP
- ARIPO
- Prior art keywords
- polypeptides
- fusion rsv
- soluble pre
- stabilized soluble
- stabilized
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
- C12N2999/002—Adverse teaching
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13172256 | 2013-06-17 | ||
PCT/EP2014/062655 WO2014202570A1 (fr) | 2013-06-17 | 2014-06-17 | Polypeptides f solubles et stabilisés du vrs en conformation pré-fusion |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2015008893A0 true AP2015008893A0 (en) | 2015-12-31 |
Family
ID=48625910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2015008893A AP2015008893A0 (en) | 2013-06-17 | 2014-06-17 | Stabilized soluble pre-fusion rsv f polypeptides |
Country Status (20)
Country | Link |
---|---|
US (1) | US10294279B2 (fr) |
EP (1) | EP3010931B1 (fr) |
JP (1) | JP6679475B2 (fr) |
KR (1) | KR102313153B1 (fr) |
CN (1) | CN105408348B (fr) |
AP (1) | AP2015008893A0 (fr) |
AU (1) | AU2014283334B2 (fr) |
BR (1) | BR112015031509B1 (fr) |
CA (1) | CA2914792C (fr) |
CL (1) | CL2015003655A1 (fr) |
EA (1) | EA034653B1 (fr) |
HK (1) | HK1223949A1 (fr) |
IL (1) | IL243053B (fr) |
MX (1) | MX362792B (fr) |
MY (1) | MY171210A (fr) |
PE (1) | PE20160045A1 (fr) |
PH (1) | PH12015502735B1 (fr) |
SG (1) | SG11201510216RA (fr) |
WO (1) | WO2014202570A1 (fr) |
ZA (1) | ZA201509140B (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS58436B1 (sr) | 2013-04-25 | 2019-04-30 | Janssen Vaccines & Prevention Bv | Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi |
KR102313153B1 (ko) | 2013-06-17 | 2021-10-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 rsv f 폴리펩타이드 |
JP6840718B2 (ja) | 2015-07-07 | 2021-03-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化された可溶性融合前rsv fポリペプチド |
PL3319633T3 (pl) * | 2015-07-07 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Szczepionka przeciwko rsv |
CN108738312A (zh) | 2015-12-23 | 2018-11-02 | 辉瑞公司 | Rsv f蛋白突变体 |
AU2017248018A1 (en) * | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
LT3439672T (lt) | 2016-04-05 | 2021-01-25 | Janssen Vaccines & Prevention B.V. | Stabilizuotas tirpus rsv f baltymas prieš suliejimą, skirtas naudoti rsv infekcijos profilaktikai |
WO2017207477A1 (fr) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Protéines f du vrs de pré-fusion solubles stabilisées |
MY194419A (en) | 2016-05-30 | 2022-11-30 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
US20200030432A1 (en) | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
JP7168938B2 (ja) | 2017-04-04 | 2022-11-10 | ユニヴァーシティ オブ ワシントン | パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用 |
WO2018211419A1 (fr) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Composition contenant un virus stable |
JP2020519666A (ja) | 2017-05-15 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定性のウイルス含有組成物 |
WO2018210871A1 (fr) * | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Procédés et compositions pour induire une immunité protectrice contre l'infection par le vrs |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
KR20200053518A (ko) | 2017-09-15 | 2020-05-18 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 면역의 안전한 유도를 위한 방법 |
EP3746090A4 (fr) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | Vaccins à base d'arn contre le vrs |
KR20210091749A (ko) * | 2018-11-13 | 2021-07-22 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합전 rsv f 단백질 |
KR20220008816A (ko) | 2019-05-15 | 2022-01-21 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료 |
US20220273787A1 (en) | 2019-05-15 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
CN114502572A (zh) | 2019-09-04 | 2022-05-13 | 华盛顿大学 | 展示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途 |
AU2021250630A1 (en) | 2020-04-02 | 2022-10-20 | Janssen Vaccines & Prevention B.V. | Stabilized vaccine compositions |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
CN115161344A (zh) * | 2022-04-26 | 2022-10-11 | 北京智飞绿竹生物制药有限公司 | 一种针对呼吸道合胞病毒感染的疫苗的制备方法 |
WO2024067723A1 (fr) * | 2022-09-29 | 2024-04-04 | 北京百邑无忧科技发展有限公司 | Protéine de fusion recombinante du virus respiratoire syncytial ayant une conformation de pré-fusion, son procédé de préparation et son utilisation |
WO2024067725A1 (fr) * | 2022-09-29 | 2024-04-04 | 北京百邑无忧科技发展有限公司 | Protéine de fusion recombinante du virus respiratoire syncytial à conformation de préfusion, son procédé de préparation et son utilisation |
WO2024069420A2 (fr) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Compositions immunogènes comprenant un trimère de protéine f rsv |
WO2024089634A1 (fr) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Compositions immunogènes contre la grippe et le vrs |
WO2024089633A1 (fr) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Molécules d'arn codant pour le vrs-f et vaccins les contenant |
CN117736278A (zh) * | 2023-12-25 | 2024-03-22 | 英诺特(唐山)生物技术有限公司 | 一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法 |
CN117586358A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0173552B1 (fr) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Composés recombinants d'ADN et l'expression de polypeptides comme le tPA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
CA2017507C (fr) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
DE69535178T2 (de) | 1994-06-10 | 2006-12-14 | Genvec, Inc. | Adenoviren-vektor systeme und zelllinien |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
DK1445322T4 (da) | 1995-06-15 | 2012-09-03 | Crucell Holland Bv | Pakningssystemer for humant rekombinant adenovirus til anvendelse ved genterapi |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
EP1707631A3 (fr) | 1996-11-20 | 2006-12-27 | Introgen Therapeutics, Inc. | Procédé amélioré pour production et purification de vecteurs d'adénovirus |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
WO1998039411A1 (fr) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Lignees cellulaires de complementation de la region e1 d'un adenovirus |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
DE69942708D1 (de) | 1998-02-17 | 2010-10-07 | Schering Corp | Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
CA2350890C (fr) | 1998-11-16 | 2014-07-08 | Introgen Therapeutics, Inc. | Compositions aqueuses pour stockage stable a long terme de particules d'adenovirus comprenant des utilisations et des procedes pour la preparation desdites compositions |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
DK1550722T3 (da) | 1999-05-17 | 2007-10-08 | Crucell Holland Bv | Rekombinant human adenovirus serotype 35 |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
US20020041884A1 (en) | 2000-03-07 | 2002-04-11 | Evans Robert K. | Adenovirus formulations |
AUPR878401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
WO2003049763A1 (fr) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition pour la conservation de virus |
CA2469721A1 (fr) | 2002-01-18 | 2003-07-31 | Schering Aktiengesellschaft | Formulations stabilisees d'adenovirus |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
EP1783212B1 (fr) | 2002-05-14 | 2011-01-05 | Merck Sharp & Dohme Corp. | Methode de purification d'adenovirus |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
US20040106184A1 (en) | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
EP1780269B1 (fr) | 2004-02-23 | 2009-07-08 | Crucell Holland B.V. | Procédés de purification de virus |
AU2006233800B2 (en) | 2005-04-11 | 2011-07-07 | Crucell Holland B.V. | Virus purification using ultrafiltration |
WO2007104792A2 (fr) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci |
WO2007110409A1 (fr) | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprenant un adénovirus recombiné et un adjuvant |
US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
EP3508505A1 (fr) | 2007-12-24 | 2019-07-10 | ID Biomedical Corporation of Quebec | Antigènes recombinants du rsv |
BRPI0921651A2 (pt) | 2008-11-03 | 2015-08-18 | Crucell Holland Bv | Método para produzir adenovírus recombinante, e partículas virais, e, biorreator |
PE20121541A1 (es) | 2009-06-24 | 2012-12-21 | Glaxosmithkline Biolog Sa | Antigenos de virus de sincicio respiratorio recombinantes |
US8889146B2 (en) | 2009-06-24 | 2014-11-18 | Glaxosmithkline Biologicals, Sa | Vaccine |
SG178026A1 (en) | 2009-07-15 | 2012-03-29 | Novartis Ag | Rsv f protein compositions and methods for making same |
DK2464664T3 (da) | 2009-08-13 | 2016-01-18 | Crucell Holland Bv | Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf |
CA2777116C (fr) | 2009-10-15 | 2020-09-01 | Crucell Holland B.V. | Procede de purification d'adenovirus a partir de cultures a haute densite cellulaire |
KR101749779B1 (ko) | 2009-10-15 | 2017-06-21 | 크루셀 홀란드 비.브이. | 아데노바이러스 입자의 정제 방법 |
WO2011050168A2 (fr) * | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Immunogènes du rsv, anticorps dirigés contre le rsv et compositions associées |
CN102762721B (zh) | 2010-02-15 | 2015-03-11 | 克鲁塞尔荷兰公司 | 用于生产Ad26腺病毒载体的方法 |
NZ703035A (en) | 2010-07-09 | 2016-06-24 | Crucell Holland Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
ES2651143T3 (es) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
SG11201405228VA (en) | 2012-03-12 | 2014-11-27 | Crucell Holland Bv | Batches of recombinant adenovirus with altered terminal ends |
SG11201405803PA (en) | 2012-03-22 | 2014-11-27 | Crucell Holland Bv | Vaccine against rsv |
JP2013247240A (ja) | 2012-05-25 | 2013-12-09 | Gigaphoton Inc | レーザ装置 |
KR102450375B1 (ko) * | 2013-03-13 | 2022-10-04 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 선융합(prefusion) RSV F 단백질 및 이의 용도 |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
AU2014255864B2 (en) | 2013-04-15 | 2019-07-18 | Janssen Vaccines & Prevention B.V. | Human antibodies binding to RSV G protein |
EP2986638A1 (fr) | 2013-04-15 | 2016-02-24 | Crucell Holland B.V. | Anticorps humains se liant à la protéine g du virus respiratoire syncytial (rsv) |
RS58436B1 (sr) | 2013-04-25 | 2019-04-30 | Janssen Vaccines & Prevention Bv | Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi |
KR102313153B1 (ko) | 2013-06-17 | 2021-10-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 rsv f 폴리펩타이드 |
-
2014
- 2014-06-17 KR KR1020167000649A patent/KR102313153B1/ko active IP Right Grant
- 2014-06-17 US US14/899,531 patent/US10294279B2/en active Active
- 2014-06-17 EP EP14731940.4A patent/EP3010931B1/fr active Active
- 2014-06-17 SG SG11201510216RA patent/SG11201510216RA/en unknown
- 2014-06-17 AP AP2015008893A patent/AP2015008893A0/xx unknown
- 2014-06-17 MX MX2015017771A patent/MX362792B/es active IP Right Grant
- 2014-06-17 PE PE2015002617A patent/PE20160045A1/es unknown
- 2014-06-17 EA EA201690031A patent/EA034653B1/ru not_active IP Right Cessation
- 2014-06-17 WO PCT/EP2014/062655 patent/WO2014202570A1/fr active Application Filing
- 2014-06-17 CN CN201480034307.1A patent/CN105408348B/zh active Active
- 2014-06-17 AU AU2014283334A patent/AU2014283334B2/en active Active
- 2014-06-17 JP JP2016520435A patent/JP6679475B2/ja active Active
- 2014-06-17 MY MYPI2015704549A patent/MY171210A/en unknown
- 2014-06-17 BR BR112015031509-7A patent/BR112015031509B1/pt active IP Right Grant
- 2014-06-17 CA CA2914792A patent/CA2914792C/fr active Active
-
2015
- 2015-12-07 PH PH12015502735A patent/PH12015502735B1/en unknown
- 2015-12-13 IL IL243053A patent/IL243053B/en active IP Right Grant
- 2015-12-15 ZA ZA2015/09140A patent/ZA201509140B/en unknown
- 2015-12-17 CL CL2015003655A patent/CL2015003655A1/es unknown
-
2016
- 2016-10-24 HK HK16112203.0A patent/HK1223949A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2914792C (fr) | 2024-02-27 |
PH12015502735A1 (en) | 2016-03-07 |
HK1223949A1 (zh) | 2017-08-11 |
NZ714594A (en) | 2021-07-30 |
SG11201510216RA (en) | 2016-01-28 |
US20160176932A1 (en) | 2016-06-23 |
ZA201509140B (en) | 2022-03-30 |
AU2014283334B2 (en) | 2018-10-18 |
BR112015031509A2 (pt) | 2017-08-29 |
MX2015017771A (es) | 2016-10-04 |
AU2014283334A1 (en) | 2015-12-17 |
EP3010931A1 (fr) | 2016-04-27 |
MX362792B (es) | 2019-02-13 |
EA201690031A1 (ru) | 2016-07-29 |
IL243053B (en) | 2020-06-30 |
EP3010931B1 (fr) | 2018-06-13 |
KR102313153B1 (ko) | 2021-10-15 |
KR20160021196A (ko) | 2016-02-24 |
PE20160045A1 (es) | 2016-02-18 |
CL2015003655A1 (es) | 2016-06-03 |
CN105408348B (zh) | 2021-07-06 |
WO2014202570A1 (fr) | 2014-12-24 |
US10294279B2 (en) | 2019-05-21 |
PH12015502735B1 (en) | 2016-03-07 |
EA034653B1 (ru) | 2020-03-03 |
CN105408348A (zh) | 2016-03-16 |
CA2914792A1 (fr) | 2014-12-24 |
BR112015031509B1 (pt) | 2023-05-09 |
JP2016522230A (ja) | 2016-07-28 |
JP6679475B2 (ja) | 2020-04-15 |
MY171210A (en) | 2019-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1223949A1 (zh) | 穩定的可溶性預融合 多肽 | |
HRP20190175T1 (hr) | Stabilizirani topljivi prefuzijski rsv f polipeptidi | |
HK1252317A1 (zh) | 新的氨基嘧啶衍生物 | |
HK1250938A1 (zh) | 穩定化的可溶性融合前rsv f多肽 | |
GB201311475D0 (en) | Polypeptides | |
SG11201602889TA (en) | Novel polypeptides | |
EP2970392A4 (fr) | Peptides sos1 stabilisés | |
AP2015008892A0 (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
GB201309421D0 (en) | Polypeptides | |
PL3080276T3 (pl) | Polipeptydy toksyczne dla owadów | |
GB201318941D0 (en) | Novel polypeptides |